XORTX Therapeutics Inc. (XRTX) Stock Ticker

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.

XRTX stock facts

What you can see for XRTX on Tickr

Live XRTX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the XRTX report.

Rankings

XRTX peers